The Latest Breaking News from Synopsys

Synopsys stock shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84.

Synopsys, Inc. (NASDAQ: SNPS) reported secon

Despite no clarity on when the Russia-Ukraine war will end, surging inflation, and logistical hindrances, the U.S. economy looks sufficiently resilient to weather the crises. Given this backdrop, we think shares of beaten-down growth stocks IQVIA (IQV), West Pharmaceutical (WST), and Synopsys (SNPS) could soar in price in the coming…

Semiconductor design and verification stock Synopsys has been displaying strong growth with a three-year EPS growth rate of 26%.

The Dow Jones gained. Twitter exploded on news Tesla CEO Elon Musk has bought shares. The Donald Trump SPAC plummeted.

Synopsys sees its Relative Strength Rating move into the 80-plus level.

If history is any guide, there may be trouble ahead for shares of Synopsys (NASDAQ:SNPS). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Synopsys (NASDAQ:SNPS) reported its Q1 earnings results on Wednesday, February 16, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Synopsys beat estimated earnings by 1.27%, reporting an EPS of $2.4 versus an estimate of $2.37.

Synopsys (NASDAQ:SNPS) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that Synopsys will report an earnings per share (EPS) of $2.37.